<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56947">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01812733</url>
  </required_header>
  <id_info>
    <org_study_id>OXN9513</org_study_id>
    <nct_id>NCT01812733</nct_id>
  </id_info>
  <brief_title>Non-interventional Study Comparing Targiniq and Oxycodone/Laxatives</brief_title>
  <official_title>An Observational Study of Quality of Life, Resource Use and Costs Associated With Treatment of Severe Pain - a Comparison of a Combination of Oxycodone and Naloxone (Targiniq) Versus Oxycodone and Laxatives</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mundipharma AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mundipharma AB</source>
  <oversight_info>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the non-interventional study is to compare the quality of life, health care
      resource use and costs between the use of a combination of oxycodone and naloxone (Targiniq)
      versus oxycodone and laxatives for patients with severe pain, and to evaluate the
      cost-effectiveness of treatment with Targiniq.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>8 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Two visits performed over 8 weeks</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Pain</condition>
  <condition>Opioid Induced Constipation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The patients have severe pain treated with opioids and will be enrolled at different
        clinics in Sweden
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male or non-pregnant female ≥18 years of age

          -  Malignant or non-malignant opioid sensitive pain

          -  Must sign an informed consent form (ICF)

          -  Must have a stable daily dose of oxycodone prolonged release formulation titrated to
             analgesic effect (as to be assessed by clinical experts)

          -  Use of laxatives for concomitant opioid-induced constipation in an adequate dose and
             length of time and without sufficient effect

          -  BFI ≥30 and state a discomfort caused by the constipation at screening

          -  Ability to answer the patient questionnaires and have an estimated overall life
             expectancy of at least six (6) months

        Exclusion criteria:

          -  History of, or on-going, abuse of alcohol and/or drugs

          -  Inability to read and understand written instructions, ICF or questionnaires

          -  Constipation not related to opioid use

          -  Unsuitable patient for other reason(s) in the opinion of the investigator

          -  Inpatients, if admission and/or discharge is expected during study period
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>/Margaret Wilson</last_name>
    <email>info@contact-clinical-trials.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jill Kiteley</last_name>
    <email>info@contact-clinical-trials.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rehabiliteringsmedicinska kliniken</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 28, 2014</lastchanged_date>
  <firstreceived_date>March 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Laxatives</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
